Structural-functional changes of myocardium and hemodynamic disturbances in patients with metabolic syndrome: Contribution of arterial hypertension in formation of total coronary risk

Kardiologiya

Volumn 45, Issue 11, 2005, Pages 11-16

  Mamedov, M N ^a   Gorbunov, V M ^a   Kiseleva, N V ^a   Oganov, R G ^a  

^a NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

Author keywords

Coronary risk; Hypertension; Left ventricular concentric hypertrophy; Metabolic syndrome

Indexed keywords

AGED; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEMODYNAMICS; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

AGED; CORONARY DISEASE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIUM; RISK FACTORS;

EID: 33645451505     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Liese A.D., Mayer-Davis E.J., Chambless L.E., Folsom A.R. Elevated fasting insulin predicts incident hypertension: the ARIC study. Atherosclerosis Risk in Communities Study Investigators. J Hypertens 1999;17:8:1169-1177.
2. Reaven G.M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003;88:6:2399-2403.
3. Laakso M., Ronnemaa T., Mykkanen L. Insulin resistance syndrome in Finland. Cardiovasc Risk Factors 1993;344:1:44-50.
4. DeSimone G., Paganisi F., Contaldo F. Link of nonhemodynamic factors to hemodymanic determinants of left ventricular hypertrophy. Hypertension 2001;38:13-18.
5. Assmann G., Cullen P., Schulte H. The Munster Heart Study (PROCAM). Eur Heart J 1998;19:Suppl A:A2-A11.
6. Ford E.S., Giles W.U., Dietz W.H. Prevalence of the metabolic syndrome among US adults. JAMA 2002;287:356-359.
7. Rodrigues-Roca G.C., Listerri-Caro J.L., Alonco-Moreno F.J. Prevalence of metabolic syndrome in the Spanish primary care population with high cardiovascular risk. Evento study. J Hypertens 2003;21:Suppl 4:S173.
8. Efstratopoulos A., Voyaki S., Baltas A. Prevalence of metabolic syndrome among Greek hypertensives. J Hypertens 2003;21:Suppl 4:92.
9. Bjorntorp P., Holm G., Rosmond R., Folkow B. Hypertension and the metabolic syndrome: closely related central origin? Blood Press 2000;9:2-3:71-82.
10. Isomaa B., Almgren P., Tuomi T., Forsen B. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:4:683-689.
11. Verdecchia P., Schillaci G., Borgioni C. et al. Ambulatory pulse pressure - a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998;32:983-998.
12. Verdecchia P. Prognostic value of ambulatory blood pressure. Current evidence and clinical implications. Hypertension 2000;35:844-851.
13. O'Brien E., Sheridan R., O'Malley K. Dippers and non-dippers (letter). Lancet 1988;2:397.
14. Verdecchia P., Reboldi G.P., Angeli F. et al. Circadian rhythm of pulse pressure in hypertension: prognostic implications. J Hypertens 2003;21:Suppl 4:S220.
15. Tin L.L., Beevers D.G., Lip G.Y. Hypertension, left ventricular hypertrophy, and sudden death. Curr Cardiol Rep 2002;4:6:449-457.
16. Arnold J.M., Yusuf S., Young J. et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003;107:9:1284-1290.
17. Stojanovic M.M., O'Brien E., Lyons S., Stanton A.V. Silent myocardial ischaemia in treated hypertensives with and without left ventricular hypertrophy. Blood Press Monit 2003;8:1:45-51.
18. Schirmer H., Lunde P., Rasmussen K. Prevalence of left ventricular hypertrophy in general population. The Tomso Study. Eur Heart J 1999;20:429-438.